Want to see HK:1652 full AI Analyst Report?
Fusen Pharmaceutical Co., Ltd. (1652) AI Stock Analysis
Fusen Pharmaceutical Co., Ltd.
(HKEX:1652)
Persistent losses, declining margins, and higher leverage are the main constraints, despite positive cash flow and a modest revenue recovery. Weak valuation and below-trend technical positioning further limit the score.
Fusen Pharmaceutical Co., Ltd. (1652) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 761.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 123.77K
- Price to Earnings (P/E)
- -273.1
- Beta (1Y)
- 0.19
- Revenue Growth
- 18.14%
- EPS Growth
- 98.32%
- Country
- Hong Kong
- Employees
- 817
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Fusen Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Fusen Pharmaceutical Company Limited operates as an investment holding enterprise, primarily engaged in the manufacturing and distribution of a diverse range of pharmaceutical products across the People's Republic of China. Its extensive product port...
Fusen Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Revenue recovered 10.5% in 2025, and operating cash flow and free cash flow were positive. However, persistent operating and net losses, margin compression, increased leverage, and reduced equity materially weaken financial performance.
Income Statement
32NegativeBalance Sheet
45NeutralCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 276.26M | 273.37M | 326.03M | 565.61M | 491.76M | 385.66M |
| Gross Profit | 109.91M | 109.79M | 162.64M | 299.51M | 225.02M | 211.13M |
| EBITDA | 37.71M | 11.55M | -25.46M | 18.93M | 49.90M | 55.82M |
| Net Income | -2.34M | -11.78M | -188.78M | -36.28M | -34.65M | 16.64M |
Balance Sheet | ||||||
| Total Assets | 1.24B | 1.26B | 1.24B | 1.34B | 1.35B | 1.24B |
| Cash, Cash Equivalents and Short-Term Investments | 87.82M | 83.88M | 21.06M | 34.85M | 128.11M | 81.70M |
| Total Debt | 313.96M | 324.34M | 383.69M | 344.12M | 228.38M | 240.69M |
| Total Liabilities | 897.11M | 891.02M | 869.80M | 781.52M | 737.38M | 582.39M |
| Stockholders Equity | 345.54M | 359.40M | 369.67M | 563.52M | 614.17M | 658.17M |
Cash Flow | ||||||
| Free Cash Flow | 36.83M | 69.98M | 57.43M | -161.84M | 86.63M | -62.37M |
| Operating Cash Flow | 87.25M | 121.93M | 133.73M | -73.33M | 110.49M | 47.77M |
| Investing Cash Flow | -31.50M | -5.88M | -163.42M | -108.32M | -13.13M | -282.98M |
| Financing Cash Flow | -44.37M | -56.21M | 15.99M | 88.50M | -51.77M | 20.53M |
Fusen Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1652, the sentiment is Positive. The current price of 1.03 is above the 20-day moving average (MA) of 0.90, above the 50-day MA of 0.85, and above the 200-day MA of 1.00, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 67.89 is Neutral, neither overbought nor oversold. The STOCH value of 95.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1652.
Fusen Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
HK:095068Neutral
HK:234859Neutral
HK:089758.6Neutral
HK:085854Neutral- HK:165243Neutral
HK:149842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0950 | 68Neutral | HKD 606.50M | 3.64 | 8.02% | 5.61% | 7.05% | 22.46% |
| HK:2348 | 59Neutral | HKD 1.39B | 5.12 | 6.78% | 6.85% | 6.55% | 36.62% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0858 | 54Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1652 | 43Neutral | HKD 757.28M | -273.12 | -0.66% | ― | 18.14% | 98.32% |
| HK:1498 | 42Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1652 | Fusen Pharmaceutical Co., Ltd. | 1.03 | 0.21 | 25.61% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.03 | -0.77 | -42.94% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% | |
| HK:2348 | Dawnrays Pharmaceutical Holdings Ltd. | 0.92 | -0.20 | -17.86% |
Fusen Pharmaceutical Co., Ltd. Corporate Events
Fusen Pharmaceutical Further Extends Completion Date for Deemed Disposal Transaction
Fusen Pharmaceutical Company Limited has announced a further extension of the completion date for a major transaction involving the deemed disposal of an equity interest in Henan Fusen Pharmaceutical Company Limited. The change relates to a capital i...
Fusen Pharmaceutical Extends Completion Date for Deemed Equity Disposal
Fusen Pharmaceutical Company Limited has announced a further extension to the completion date of a major transaction involving a deemed disposal of equity interest in Henan Fusen Pharmaceutical Company Limited. The capital increase price payment date...
Fusen Pharmaceutical Narrows Interim Loss as Gross Profit Rises
Fusen Pharmaceutical reported unaudited interim results for the six months ended 30 June 2026, showing revenue growth of about 2.5% to RMB114.1 million and a 14.2% increase in gross profit to RMB49.1 million. The company narrowed its loss attributabl...
Fusen Pharmaceutical Sets Board Meeting to Review Interim Results and Dividend
Fusen Pharmaceutical Company Limited has scheduled a board meeting for 31 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026, and to consider their release to the market. The board will also delibera...
Fusen Pharma Wins Spot for Four Drugs in China’s Latest Centralised Procurement Round
Fusen Pharmaceutical Company Limited said four of its drugs, including nicardipine injection, azilsartan medoxomil potassium tablets, compound potassium hydrogen phosphate injection and dydrogesterone tablets, have been selected in the twelfth batch...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026